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Abstract
Background: Obesity is associated with increased risk of cardiovascular disease. Arterial stiffness assessed by
carotid femoral pulse wave velocity (PWV) is an independent predictor of cardiovascular morbidity and mortality.
We aimed to investigate how various measures of body composition affect arterial stiffness.
Methods: This is an analysis of cross-sectional baseline data from a controlled clinical trial addressing changes in
arterial stiffness after either surgery or lifestyle intervention in a population of morbidly obese patients. High-fidelity
applanation tonometry (Millar®, Sphygmocor®) was used to measure pulse wave velocity (PWV). Carotid femoral
PWV is a direct measure of arterial stiffness and is considered to be the gold standard method. The Inbody 720
Body Composition Analyzer was used for bioelectrical impedance analysis (BIA). Spearman’s correlation,
independent samples t-test, chi-square tests, Fisher’s exact test and multiple linear regression analyses were used as
statistical methods.
Results: A total of 133 patients (79 women), with a mean (SD) age of 43 (11) years were included in the study.
Men had a significantly higher prevalence of obesity related comorbidities and significantly higher PWV, 9.1 (2.0)
m/s vs. 8.1 (1.8) m/s, p = 0.003, than women. In the female group, PWV was positively correlated with WC, WHtR,
BMI and visceral fat area. In the male group, PWV was negatively correlated with BMI. Multiple linear regression
analysis showed that increasing BMI, WC, WHtR, visceral fat area and fat mass were independently associated with
higher PWV in women, but not in men, after adjustment for age, hypertension and type 2 diabetes.
Conclusion: Most measures of general and abdominal obesity were predictors of arterial stiffness in female
morbidly obese patients.
Trial registration: ClinicalTrials.gov Identifier NCT00626964
Background
The prevalence of obesity is rising globally, independent
of ethnicity, race and age, and is associated with
increased mortality and morbidity [1,2]. Obesity rates in
Scandinavia represent no exception [3-5]. Importantly,
the prevalence of morbid obesity, defined as BMI ≥ 40.0
kg/m2 or BMI 35.0 -39.9 kg/m2 and an obesity-related
comorbidity, is increasing at an even steeper rate [6].
Two percent of the Norwegian population [7] can be
classified as morbidly obese.
Several lines of evidence indicate that the distribution
of fat is a major determinant of cardiovascular risk in
both normalweight, overweight and moderately obese
subjects [8-10], although measures of general obesity
and physiological differences between genders must also
be considered [11-13]. Only a few studies in morbidly
obese subjects have compared the effect of overall and
central obesity on cardiovascular risks and the results
have been inconsistent both within, and between gen-
ders [14-16]. Other studies have reported an increased
risk of death in persons with BMI > 35 kg/m2 [17,18],
but the increase in mortality has been linked to comor-
bidities rather than the obesity [19] suggesting that
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morbid obesity without comorbidities is not a cardiovas-
cular risk factor regardless of fat distribution.
Nevertheless, obesity is a major modifiable risk factor
for coronary artery disease (CAD) that imparts a degree
of cardiovascular risk similar to that associated with
hypertension, hyperlipidemia, smoking and sedentary
lifestyle [20]. Accordingly, it seems to be a paradox that
the increasing obesity rates coincide with a decreased
risk of cardiovascular death [21]. The latency time for
developing cardiovascular disorders may, however, be
several decades [22,23]. Thus, early risk markers are
needed to identify obese subjects at risk.
Arterial stiffness assessed by pulse wave velocity
(PWV) is an independent predictor of cardiovascular
morbidity and mortality [24,25], and PWV is increas-
ingly recognized as a valid surrogate endpoint of cardio-
vascular disease [26,27].
The main objective of this study was to examine the
possible relationship between various measures of body
composition and arterial stiffness PWV. We hypothe-
sized that in morbidly obese subjects abdominal obesity




This is an analysis of cross-sectional baseline data from
a non-randomized clinical trial comparing the effects of
a comprehensive lifestyle modification program and
bariatric surgery on arterial stiffness in morbidly
obese patients. (http://ClinicalTrials.gov Identifier
NCT00626964).
Setting
The study was performed at a tertiary care centre (the
Morbid Obesity Centre, Vestfold Hospital Trust,
Tønsberg, Norway) between February 2008 and January
2010. Before inclusion patients were either assigned to a
comprehensive lifestyle modification program at the
Hospital for Rehabilitation, Stavern, or to bariatric sur-
gery at the Morbid Obesity Centre.
Participants and study size
All participants were recruited from our tertiary care
centre and had to reside within 100 km of either the hos-
pital for rehabilitation or our clinic. The patients in the
intensive lifestyle intervention group were all selected
from patients that had signed up for participation in a
standardized health promoting and weight reductive pro-
gram at the hospital for rehabilitation. Participants in the
surgery group were selected from patients preparing for
bariatric surgery at our hospital. The decision regarding
the type of intervention was made prior to the inclusion
to our study and was not a part of our protocol. Patients
with one of the following conditions or diseases were
excluded; uncompensated heart failure, cardiac arrhyth-
mias, unstable angina, end-stage renal disease, known
bleeding disturbances, serious psychiatric disorders, ser-
ious eating disorders, cardiac pacemakers, intra-cardiac
devices, cerebrovascular event or a myocardial infarction
within the last six months. The inclusion period started
February 2008 and ended February 2010. Initially, 148
patients accepted our invitation to participate in the
study, 15 patients withdrew their consent before the
study started, leaving a total of 133 patients in the pre-
sent analysis. The study was approved by the regional
ethics committee of the Southern Norway Regional
Health Authority, and was performed in accordance with
the Declaration of Helsinki [28]. Written informed con-
sent was provided by all participants.
Variables
The main outcome variable was arterial stiffness mea-
sured by PWV. The main explanatory variables were
various measures and estimates of body composition,
including anthropometric characteristics (WC, WHR,
WHtR, BMI), data from bioelectrical impedance analysis
(BIA) [visceral fat area (cm2), fat mass (kg) and fat free
mass (kg)]. Potential confounders adjusted for were age,
type 2 diabetes and arterial hypertension.
Data sources and measurements
All participants underwent a medical examination per-
formed by a physician and a trained nurse. Blood was
collected by venipuncture following an overnight fast on
the day of medical examination. Weight and height
were measured with patients wearing light clothing and
no shoes. BMI was calculated as weight in kilograms
divided by the square of the height in meters. WC (cm)
was measured midway between the 12th rib and the
iliac crest. Blood pressure was measured after five min-
utes of rest using an electronic auscultatory blood pres-
sure recorder with an appropriately sized cuff based on
the measurement of arm circumference (Dinamap®,
ProCare Series, G.E. Medical Systems) with the patient
sitting in the upright position. Three measurements
were recorded, and the average of the second and third
measurement was recorded and used in the analysis.
Bioelectrical impedance measures were collected using
the Inbody 720, Body Composition Analyzer, Biospace
Co. Ltd. Arterial hypertension was defined by either, a
systolic blood pressure ≥ 140 mmHg, diastolic blood
pressure ≥ 90 mmHg or the use of antihypertensive
medication. Ischemic heart disease was defined as a his-
tory of stable coronary artery disease, percutaneous cor-
onary intervention, coronary artery bypass graft surgery
or myocardial infarction. The statistical analysis was per-
formed using SPSS 16.0 (SPSS Inc., Chicago, IL).
Nordstrand et al. BMC Cardiovascular Disorders 2011, 11:7
http://www.biomedcentral.com/1471-2261/11/7
Page 2 of 8
Pulse wave velocity
The measurement of PWV is generally accepted as the
simplest, non-invasive, robust, and reproducible method
to determine arterial stiffness and is considered to be
the gold standard method [29-32]. ]. The Sphygmocor
system (Artcor, Sidney, Australia) and a single high-fide-
lity applanation tonometer (Millar®) were used to mea-
sure PWV. Pulse waves were obtained sequentially from
the carotid and femoral artery. The PWV was calculated
from the transit time and the distance between these
two arterial sites, determined in relation to the R-wave
of the ECG, with patients lying in a horizontal position.
Three complete sets of data were sampled and the aver-
age value was used as result. Bioelectrical impedance
analysis was obtained using Inbody 720, Body Composi-
tion Analyzer, Biospace Co. Ltd. Each patient was
undressed except for underwear, and placed in an
upright position on the body composition analyzer. All
jewelry and wristwatches were removed before the ana-
lyzer started recording. The InBody 720 uses the seg-
mental BIA method in order to examine the body as
five cylinders (four limbs and a trunk), and measures
impedance in these parts separately. It also uses electri-
cal current at multi-frequency (5, 50, 250, 500 and 1000
kHz) in order to directly measure the amount of extra-
cellular and intracellular water. Homeostasis Model
Assessment Insulin Resistance (HOMA- IR) was calcu-
lated as ([fasting serum glucose (mmol/l) × fasting
serum insulin (pmol/l)]/135 [33]. Low-density lipopro-
tein cholesterol (LDL) concentrations were estimated
by the Friedewald equation: LDLcholesterol = Total-
cholesterol - HDL-cholesterol - (0.45 × triglycerides)
[34]. S-LDL cholesterol was not calculated if S-triglycer-
ides were < 0.2 mmol/L or ≥ 5 mmol/L.
Laboratory analyses
Analyses of serum glucose and blood lipids were per-
formed using dry reagent slide technology on the Vitros
FS 5.1 (Ortho-Clinical Diagnostics, New York, USA).
Glycated hemoglobin (HbA1c) was analyzed using high
performance liquid chromatography on Tosoh HLC-723
G7 (Tosoh Corporation, Tokyo, Japan). Sera for analysis
of insulin were stored at - 20°C and analyzed within one
week of blood sampling (Linco Research Inc, St. Charles,
MO). Immunoturbidimetric method was used for deter-
minations of apolipoprotein A-1 and apolipoprotein B
(Modular, Roche Diagnostic GmbH).
Statistical methods
Data are given as mean (SD) or n (%). Skewed data were
ln-transformed to approximate normality before statisti-
cal analyses (HOMA-IR, S-f-glucose, S-f-insulin and
S-triglycerides). Spearman’s rank correlation was used to
assess the bivariate association between the outcome
and each of the exposure variables. Gender differences
were analyzed using independent samples t-test for con-
tinuous data, whilst Fisher’s exact tests were used for
categorical data. The multiple linear regression analyses
included the various measures of body composition, age,
hypertension and type 2 diabetes as independent vari-
ables, and aortic PWV as dependent variable. Significant
interactions between gender and BMI (p < 0.001), WC
(p = 0.019) and WHtR (p < 0.001) made it appropriate
to perform gender specific linear regression analyses.
Semi-partial (part) correlation coefficients were squared
in order to calculate the percentage of total variance in
the dependent variable explained by a given independent
variable.
Results
A total of 133 morbidly obese persons (79 women), with
a mean (SD) age of 43 (11) years, were included in the
study. One hundred and six patients (59 women) had a
BMI ≥ 40 kg/m2. Thirty one patients (24 women) were
morbidly obese based on BMI alone (no comorbidity
and BMI ≥ 40 kg/m2), whilst 27 patients (18 women)
had a BMI between 35 and 40 kg/m2. Demographic
characteristics, body composition and cardiovascular
risk factors according to gender are shown in Table 1.
The male patients had a significantly higher prevalence
of hypertension, type 2 diabetes and ischemic heart dis-
ease, as well as higher levels of fasting insulin, glucose
and HbA1c than the female patients. Conversely, men
had lower levels of total cholesterol, LDL-cholesterol
and HDL-cholesterol than women. The male patients
had higher PWV than the female patients, [mean (SD)
9.1 (2.0) m/s vs. 8.1 (1.8) m/s, p = 0.003].
Women
In the female group, PWV was positively correlated with
BMI, WC and WHtR (Figure 1). Table 2 shows that
PWV was significantly correlated with visceral fat area,
fasting glucose, HbA1c and the usage of b-blockers and
calcium-channel blockers. Multiple linear regression
analysis showed that BMI, WC, WHtR, visceral fat area
and fat mass, but not WHR, were significantly asso-
ciated with PWV after adjustment for age, hypertension
and type 2 diabetes (table 3). Based on part correlation
BMI explained 14% of the variation in PWV, with
WHtR explaining 12%, fat mass 8%, visceral fat area 8%
and WC 6%.
Men
In the male group, PWV showed a significant negative
correlation with BMI (Figure 1). The use of calcium-
channel blockers, inhibitors of the RAA-system, statins
and fasting glucose were positively correlated with PWV
(Table 2). BMI showed a negative association with age,
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r = -0.449, p = 0.001. Multiple linear regression analysis
(Table 3) did not demonstrate any significant association
between measures of body composition and PWV after
adjustment for age, hypertension and type 2 diabetes.
Discussion
Key results
Our results indicate that measures of both general obe-
sity and abdominal obesity are associated with PWV in
morbidly obese women, but not in men. Thus, we could
not confirm our initial hypothesis that abdominal obe-
sity was a better predictor of aortic stiffness than general
obesity.
Comparison with previous studies
Our results support the findings of a previous study of
normal weight and less obese European Caucasians
which demonstrated that PWV increased with higher
BMI in middle-aged and older women, but not in men
[35]. Further, we are able to extend these findings to be
valid in morbidly obese women. Partly in contrast with
our findings, WC, but not BMI, was significantly
associated with PWV in a cross-sectional study of mid-
dle aged, apparently healthy subjects [36]. In addition,
no significant correlation between BMI and PWV was
revealed in a recent prospective study of 29 morbidly
obese subjects [37]. These discrepancies might have sev-
eral explanations, including the low percentage of obese
participants in the former study and the low number of
participants in the latter. On the other hand, a study of
less obese African-Americans and whites demonstrated
that increased BMI, WC, and WHR were associated
with higher PWV in both men and women [38]. Finally,
baseline data from a longitudinal study of 50 (12 men)
healthy obese patients (BMI > 30 kg/m2) [39] showed
that BMI and total fat mass, but not visceral fat mass,
assessed by magnetic resonance imaging, were signifi-
cantly associated with PWV in both genders. The latter
is in opposition to our finding of a significant associa-
tion between visceral fat area assessed by BIA and PWV
in women. This difference in results might partly be
explained by the higher degree of obesity in our study
population and the larger proportion of metabolic
disorders.
Table 1 Demographic characteristics, body composition, metabolic parameters and medications of 133 morbidly
obese patients
Variable Total (n = 133) Male (n = 54) Female (n = 79) P-value
Age (years) 43 (11) 45 (11) 41 (10) 0.107
Hypertension* (yes/no) 90 (68%) 44 (81%) 46 (58%) 0.005
Type 2 diabetes (yes/no) 38 (29%) 25 (46%) 13 (17%) <0.001
Ischemic heart disease (yes/no) 7 (5.3%) 6 (11.1%) 1 (1.3%) 0.018
Current smoker (yes/no) 20 (15%) 6 (11%) 14 (18%) 0.340
Weight (kg) 132 (22) 146 (23) 121 (16) <0.001
Various measures of body composition
Waist-to-hip ratio 0.99 (0.10) 1.17 (0.07) 0.94 (0.07) <0.001
Waist-to-height ratio 75.3 (6.4) 79.2 (6.2) 74.4 (5.9) <0.001
Waist circumference (cm) 131 (14) 142 (12) 124 (10) <0.001
BMI (kg/m2) 44.5 (5.6) 46.1 (6.3) 43.5 (4.8) 0.008
Fat mass (kg) 63 (13) 66 (16) 61 (11) 0.055
Fat free mass (kg) 69 (13) 81 (10) 61 (7) <0.001
Visceral fat area (cm2 ) 242 (48) 262 (55) 228 (37) <0.001
Metabolic variables
apoB/apoA-1 ratio 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.550
Fasting insulin (pmol/L) 100 (85) 125 (120) 87 (49) 0.048
HOMA-IR† 4.6 (4.4) 6.1 (6.3) 3.5 (2.0) 0.002
Fasting glucose (mmol/l) 6.0 (2.2) 6.5 (2.7) 5.4 (1.1) 0.002
B-HbA1c (%) 6.2 (1.3) 6.5 (1.6) 5.7 (0.7) 0.001
Pulse pressure (mmHg) 62 (16) 63 (15) 61 (17) 0.471
Medication
b-blocker (yes/no) 13 (10%) 8 (15%) 5 (6%) 0.134
Calsium-channel blocker (yes/no) 17 (13%) 10 (19%) 7 (9%) 0.125
Inhibitors of the RAA-system (yes/no) 37 (28%) 23 (43%) 14 (18%) 0.003
Statins (yes/no) 18 (14%) 13 (24%) 5 (6%) 0.008
Data are given as number (%) or mean (SD). *Hypertension is defined by the patient receiving antihypertensive medication or having systolic blood pressure ≥
140 mmHg or diastolic blood pressure ≥ 90 mmHg. † Homeostasis Model Assessment Insulin Resistance.
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Gender differences
It is well known that for any given BMI, men have a lar-
ger amount of visceral adipose tissue and a higher risk
of cardiovascular disease than women [13]. Our results
are in agreement with this. Accordingly, our findings are
discussed separately in men and women [40]. In the pre-
sent study we observed an apparent lack of association
between obesity and PWV among male patients in the
multivariate analysis (Table 3). This might partly be
explained by a significantly higher prevalence of
Figure 1 Correlations between anthropometric measures and PWV. The scatterplots show the relationship between anthropometric
measures and PWV.
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comorbidities and conditions known to increase PWV;
such as hypertension, type 2 diabetes, ischemic heart
disease and insulin resistance in our male population.
Conversely, a weak negative correlation between BMI
and PWV was shown in the univariate analysis of male
subjects (Figure 1). This surprising finding might partly
be explained by the coexistence of a significant negative
correlation between age and BMI and the moderate
positive correlation between age and PWV in our study.
Finally, we cannot exclude the possibility that the
number of male patients was too low to reveal a possi-
ble association between obesity and PWV.
Body Composition
The associations between various measures of overall
and abdominal obesity and PWV in women were com-
parable in the present study. However, the amount of
fat tissue associated with morbid obesity is likely to
cause an accumulation of both visceral and subcuta-
neous fat. The effect of this can be a loss of superiority
of one anthropometric measure of obesity to the other.
Another area of concern is the relatively low reliability
of the different anthropometric measures in this popula-
tion[41]. This could imply that the correlations are
underestimated and thus should be interpreted with
caution. In addition, and in accordance with previous
studies [9,42], the anthropometric indexes taking height
into account (BMI and WHtR) seemed to explain a lar-
ger part of the variation in PWV than WC, visceral fat
area and fat mass. Accordingly, the usage of WC may
underestimate the relative amount of abdominal fat in
short subjects and overestimate it in tall subjects and
consequently be misleading.
It is difficult to explain the lack of association between
WHR and PWV in our study. This finding is in opposi-
tion to several other studies designed to explore the pre-
dictive value of various measures of obesity in relation
to cardiovascular risk factors [43]. The detrimental
effects of abdominal obesity may mitigate against the
possible protective effect of subcutaneous fat located at
the hip, despite only slightly increased WHR in mor-
bidly obese patients. The low reliability of WHR as com-
pared with WC in a morbidly obese population is also a
factor that should be considered [41].
Other factors related to arterial stiffness
In accordance with a recent study [44] demonstrating a
significant association between fasting glucose and PWV
in middle aged overweight and obese subjects, we found a
significant positive correlation between fasting glucose and
PWV in both men and women. In women, but not in
men, we also found a positive correlation between HbA1c
and PWV. Conversely, we could not demonstrate any
association between HOMA-IR and PWV as shown in the
previous study [44]. An elevated glucose level can cause a
non-enzymatic glycation of matrix proteins and result in
the accumulation of glycation end-products within the
arterial wall and subsequent arterial stiffness [45].
Limitations and strengths
The major strengths of the present study are that
arterial stiffness is a well validated risk marker of cardio-
vascular morbidity and mortality, as well as that PWV is
considered to be the “gold standard” in assessing arterial
Table 2 Correlations between PWV, body composition,
metabolic parameters and medications
Independent variables Male (r) Female (r)
Age 0.61† 0.52†
Hypertension‡ 0.19 0.59†
Type 2 diabetes (yes/no) 0.46† 0.18
Visceral fat area (cm2) -0.18 0.25*
Fat mass (kg) -0.26 0.06
Fat free mass (kg) -0.15 -0.04
apo-B/apoA-1 ratio -0.29 0.10
Fasting insulin (mmol/L) 0.03 0.09
HOMA IR§ 0.10 0.13
Fasting glucose (mmol/L) 0.35* 0.24*
HbA1c (%) 0.27 0.31*
b-blocker (yes/no) 0.12 0.39†
Calsium-channel blocker (yes/no) 0.36* 0.24*
Inhibitors of the RAA-system (yes/no) 0.29* 0.14
Statins (yes/no) 0.39* 0.22
*p < 0.05. †p < 0.001. ‡ Hypertension is defined by the patient receiving
antihypertensive medication or having systolic bloodpressure ≥ 140 mmHg or
diastoic blood pressure ≥ 90 mmHg. §Homeostasis Model Assessment Insulin
Resistance.
Table 3 Independent predictors of PWV after adjustment
for age, hypertension and type 2 diabetes.
Body composition Β 95% CI P R Square
Female
Body mass index (kg/m2) 0.129 0.068 to 0.190 <0.001 0.42
Waist circumference (cm) 0.047 0.010 to 0.083 0.013 0.33
Waist-to-hip ratio -1.297 -6.109 to 3.522 0.594 0.28
Waist-to-height ratio 0.108 0.052 to 0.164 <0.001 0.40
Visceral fat area (cm2) 0.014 0.005 to 0.024 0.004 0.35
Fat mass (kg) 0.047 0.015 to 0.080 0.004 0.35
Fat free mass (kg) 0.009 -0.046 to 0.065 0.736 0.27
Male
Body mass index (kg/m2) -0.009 -0.083 to 0.065 0.806 0.47
Waist circumference (cm) 0.014 -0.023 to 0.052 0.440 0.48
Waist-to-hip ratio 1.933 -3.707 to 7.574 0.494 0.48
Waist-to-height ratio 0.021 -0.053 to 0.094 0.575 0.48
Visceral fat area (cm2) 0.003 -0.005 to 0.011 0.470 0.49
Fat mass (kg) 0.005 -0.024 to 0.035 0.719 0.48
Fat free mass (kg) 0.008 -0.033 to 0.050 0.693 0.48
Multiple linear regression analysis.
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stiffness. In terms of weaknesses, the cross-sectional
design of the study necessarily implies that we cannot
establish a cause-effect relationship. All but one partici-
pant, were white, and we are thus unable to generalize
our results to non-white populations. It should also be
noted that BIA is not considered to be a “gold standard”
method. BIA has a tendency to underestimate the
amount of fat tissue in morbidly obese patients when
compared to hydrostatic weighing and dual-energy X-
ray absorptiometry [46-48], although this is minimized
by the usage of the segmental BIA method and multifre-
quency technology in the present study.
Conclusion
Most measures of general and abdominal obesity were
associated with arterial stiffness in morbidly obese
women.
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